Interim Results From WHO’s Solidarity Trial Show Remdesivir, Interferon, Other Treatments Show Little Or No Impact On Survival Among Hospitalized COVID-19 Patients

Science: Remdesivir and interferon fall flat in WHO’s megastudy of COVID-19 treatments
“One of the world’s biggest trials of COVID-19 therapies released its long-awaited interim results yesterday — and they’re a letdown. None of the four treatments in the Solidarity trial, which enrolled more than 11,000 patients in 400 hospitals around the globe, increased survival — not even the much-touted antiviral drug remdesivir. Scientists at the World Health Organization (WHO) released the data as a preprint on medRxiv last night ahead of its planned publication in the New England Journal of Medicine…” (Kupferschmidt, 10/16).

Additional coverage of the study’s interim results is available from Financial Times, The Hill, New York Times, Reuters, and The Telegraph.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.